An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Trial Profile

An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Bavituximab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2017 Status changed from suspended to discontinued.
    • 13 Apr 2016 This trial was prematurely terminated in Germany, according to the European Clinical Trials Database.
    • 08 Mar 2016 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top